论文信息 - Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia - 字舞流文

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

T. Cluzeau | J. Liesveld | P. Rousselot | D. Rizzieri | G. Roboz | T. Braun | D. Bixby | Li Zhou | A. Pigneux | S. Botton | E. Stein | D. Roth | R. Cook | P. Peterlin | A. Volkert | D. Lebon | M. Kelly | Q. Kang-Fortner | Maël Heiblig